Hong Kong-listed InSilico sad the deal could be valued at as much as $2.75 billion. ...

"By deploying AI technologies that scale from biomarkers to life models, world models of human and animal life, we can identify multi-purpose targets driving multiple diseases at the same time," said Alex Zhavoronkov, founder and CEO of Insilico Medicine. Eli Lilly extends partnership with Insilico Medicine for AI-powered drug discovery | Reuters Lilly and Insilico had signed a research collaboration in November, broadening a partnership that began with an AI-based software licensing agreement in 2023. Excl ...

2026年3月30日 星期一 1 国新办将于3月30日就第六届中国国际消费品博 览会有关情况举行新闻发布会 2 上交所对《上海证券交易所基金业务指南第2号 -- 上市基金做市业务》进行了修订,并自3月30 日起实施 3 2026 IEAE深圳消费类电子展将于3月30日至4 月1日举办 4 法国G7财长及能源部长召开会议, 讨论释放战 略石油储备议题 1 国防部派团赴欧洲举行机制性对话 3月23日至29日，中国国防部派团赴欧盟、北约总部及瑞士分别举行第15次中国－欧盟防务部门安全政策对话、第9次中国－北约安全政策对话和第15次中瑞 国防部工作对话，围绕国际和地区安全形势等共同关心的问题深入交换意见。（央视新闻） 2 中国人民解放军南部战区位中国黄岩岛领海领空及周边区域组织战备警巡 3月29日，中国人民解放军南部战区组织海空兵力位中国黄岩岛领海领空及周边海空域开展战备警巡。黄岩岛是中国固有领土。3月份以来，战区部队海空兵 力持续加强黄岩岛领海周边海空域巡逻警戒，依法依规开展跟踪监视、警告驱离，有力有效应对各类侵权挑衅行径，坚决捍卫国家主权安全，坚定维护南海 地区和平稳定。（南部战区） 3 北京启动智能网联新能源汽 ...

Eli Lilly and Company (NYSE:LLY) is one of the Good Stocks to Buy Now. On March 20, Jefferies reiterated a Buy rating on Eli Lilly and Company (NYSE:LLY) with a price target of $1,300. ​The rating is based on the company’s prescription data for GLP-1 medications. Oral Wegovy had roughly 89,300 IMS prescriptions and 76,800 Symphony prescriptions in the 10th week of its launch. The data outpace comparable launches of injectable Wegovy and Zepbound. ​On the other hand, data from other GLP-1 drugs witnessed ...

BEIJING — U.S. pharmaceutical giant Eli Lilly has reached a $2.75 billion deal to bring drugs developed using artificial intelligence by Hong Kong-based Insilico Medicine to the global market.The agreement will give Insilico $115 million up front, with the remainder subject to regulatory and commercial milestones, along with royalties on future sales, according to the companies' announcement Monday.Insilico has developed at least 28 drugs using generative AI tools, with nearly half already at a clinical sta ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 INSILICO MEDICINE InSilico Medicine Cayman TopCo 英矽智能 （於開曼群島註冊成立的有限公司） （股份代號：3696） 自願公告 英矽智能宣佈與禮來達成一項全球管線授權與AI藥物研發合作 本公告由英矽智能（「本公司」，連同其附屬公司統稱「本集團」或「英矽智能」）自 願作出，以告知本公司股東及潛在投資者有關本集團的最新業務更新。 根據相關協議條款，英矽智能將有資格獲得1.15億美元首付款，並在後續達成開 發、監管及商業化里程碑後獲得進一步付款，使交易總價值最高可達約27.5億美 元；此外，英矽智能還將獲得基於未來銷售額的分級特許權使用費。 關於英矽智能 英矽智能是一家全球先鋒生物科技公司，致力於整合人工智能和自動化技術，加 速藥物發現並推動生命科學領域的創新，賦能人類擁有更長久、更健康的生活。 2025年12月30日，本公司於香港聯合交易所主板掛牌上市，股票代碼 ...

Sign up here. Eli Lilly to sign $2 billion deal for AI drug development with Hong Kong's Insilico Medicine, FT says | Reuters Reuters could not immediately verify the report. Exclusive news, data and analytics for financial market professionalsLearn more aboutRefinitiv A drone view shows the Eli Lilly logo on one of the company's offices in San Diego, California, U.S., November 21, 2025. REUTERS/Mike Blake Purchase Licensing Rights, opens new tab March 29 (Reuters) - Eli Lilly (LLY.N), opens new tabwill si ...

Taltz and Zepbound used together provided comprehensive improvements in disease activity and patient- reported outcomes compared to Taltz monotherapy in TOGETHER-PsA study Late-breaking results also published in Arthritis & Rheumatology INDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in ...

医药周报 20260322 再次强调 2026 年重视供应链(CXO 和上游板块)，聊聊选股思路 glmszqdatemark 医药行情回顾&分析&近期判断 周专题：再次强调 2026 年重视供应链(CXO 和上游板块)，聊聊选股思路 1）整体：2H24/2H25 新药供应链分别迎来海外/国内需求的复苏，2026 年有望进入内外需共振叠 加创新迭代共同驱动的业绩景气区间，前端/临床端/CDMO 各有叙事，随着地缘政治风险短期落地 和业绩期催化，CXO 及上游板块有望走出行情。 2）短期：4Q25 延续向好趋势，临近业绩期，持续看好龙头公司兑现的确定性和强度。受益于国内 外产业趋势。外需方向 2024 年底开始进入复苏轨道，内需方向在 2025 年下半年复苏，产业趋势确 定性较高，横向比较来看主要公司业绩兑现的能力具有稀缺性。礼来明星产品 Orforglipron 有望较 快获批，关注礼来中国供应链建设过程中有望受益的 CDMO 龙头/细分领域优势公司。O 药为小分 子口服 GLP-1，合成工艺复杂严苛，涉及多手性中心控制、晶型控制及稳定性要求，关注在高壁垒 复杂领域具有较强能力的小分子 CDMO 一体化龙头， ...

PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 - 24/7 Wall St. S&P 5006,362.40 -2.11% Nikkei 22551,507.00 -2.23% Investing PPH ETF: Drug Pricing Policy and Eli Lilly Concentration Are the Two Risks to Watch in 2026 By Michael WilliamsPublished Mar 28, 7:15AM EDT Quick Read VanEck Pharmaceutical ETF (PPH) is 17.91% concentrated in Eli Lilly (LLY), which has fallen 16% year-to- date as generic GLP-1 competition and patent expirations in emerging markets threaten ...